scaffoldtx.com
Open in
urlscan Pro
199.60.103.191
Public Scan
Submitted URL: https://email.em.rdhgroups.com/c/eJxskbuO2zAQRb9G7GhQfElTsAgWsIt4ESSdK4GP4UoIZSoU5c3-fSABAVy4ncE9g7nHD1Mwt68bKjHa7-whL-lt8-_xFw...
Effective URL: https://scaffoldtx.com/
Submission: On December 21 via manual from US — Scanned from DE
Effective URL: https://scaffoldtx.com/
Submission: On December 21 via manual from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
NEWSLETTER CONTACT US DECODING THE TRANSCRIPTOME A PLATFORM FOR DRUG DISCOVERY IN RNA BIOLOGY Scaffold Therapeutics is advancing a unique pipeline of assets targeting clinically validated and first in class biology in oncology, neurodegeneration and other therapeutic areas OUR RESEARCH IS FOCUSED ON REGULATING MODIFICATIONS OF RNA THAT CONTROL ITS STABILITY, TRANSCRIPTION AND DEGRADATION. MANAGEMENT TEAM JEFF CARTER CEO Founder RENE LEMIEUX, PHD CSO JEFF HIXON Strategy and Operations FRANCESCO SALITURO, PHD Head of Drug Discovery BOARD AND ADVISORS WASIM MALIK, PHD Board Member KATHLEEN BURNS, MD, PHD Clinical Advisor EYTAN STEIN, MD Clinical Advisor STUART CHAFFEE, PHD Business Advisor YADIRA SOTO-FELICIANO, PHD Scientific Advisor AMEDEO CAFLISCH, PHD Academic Collaborator and Advisor NOW PARTNERED WITH QUREALZ! Scaffold Therapeutics has partnered with QureALZ - a company dedicated to sponsoring breakthrough research on Alzheimer's and other neurodegenerative disorders. This partnership will leverage Scaffold's drug discovery platform and world class drug discovery team to advance research into a range of diseases from Alzheimer's disease to ALS to brain cancer. © 2023 Scaffold Therapeutics Inc. All rights reserved Privacy Policy